NanoNet: Rapid and accurate end-to-end nanobody modeling by deep learning
Antibodies are a rapidly growing class of therapeutics. Recently, single domain camelid VHH antibodies, and their recognition nanobody domain (Nb) appeared as a cost-effective highly stable alternative to full-length antibodies. There is a growing need for high-throughput epitope mapping based on ac...
Main Authors: | Tomer Cohen, Matan Halfon, Dina Schneidman-Duhovny |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.958584/full |
Similar Items
-
Development of nanobodies targeting hepatocellular carcinoma and application of nanobody-based CAR-T technology
by: Keming Lin, et al.
Published: (2024-04-01) -
Nanobodies and Nanobody-Based Human Heavy Chain Antibodies As Antitumor Therapeutics
by: Peter Bannas, et al.
Published: (2017-11-01) -
Nanobodies: A Review of Generation, Diagnostics and Therapeutics
by: Bo-kyung Jin, et al.
Published: (2023-03-01) -
Institute collection and analysis of Nanobodies (iCAN): a comprehensive database and analysis platform for nanobodies
by: Jing Zuo, et al.
Published: (2017-10-01) -
Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody
by: Mengmeng Ji, et al.
Published: (2024-02-01)